首页> 外文OA文献 >Spread and control of COVID-19 in China and their associations with population movement, public health emergency measures, and medical resources
【2h】

Spread and control of COVID-19 in China and their associations with population movement, public health emergency measures, and medical resources

机译:传播与COVID-19在中国及其与人口流动,突发公共卫生事件应急措施协会控制和医疗资源

摘要

ABSTRACT BACKGROUND The COVID-19 epidemic, first emerged in Wuhan during December 2019, has spread globally. While the mass population movement for Chinese New Year has significantly influenced spreading the disease, little direct evidence exists about the relevance to epidemic and its control of population movement from Wuhan, local emergency response, and medical resources in China. METHODS Spearman's correlation analysis was performed between official data of confirmed COVID-19 cases from Jan 20th to Feb 19th, 2020 and real-time travel data and health resources data. RESULTS There were 74,675 confirmed COVID-19 cases in China by Feb 19th, 2020. The overall fatality rate was 2.84%, much higher in Hubei than in other regions (3.27% vs 0.73%). The index of population inflow from Hubei was positively correlated with total (Provincial r=0.9159, p<0.001; City r=0.6311, p<0.001) and primary cases (Provincial r=0.8702, p<0.001; City r=0.6358, p<0.001). The local health emergency measures (eg, city lockdown and traffic control) were associated with reduced infections nationwide. Moreover, the number of public health employees per capita was inversely correlated with total cases (r=-0.6295, p<0.001) and infection rates (r=-0.4912, p<0.01). Similarly, cities with less medical resources had higher fatality (r=-0.4791, p<0.01) and lower cure rates (r=0.5286, p<0.01) among the confirmed cases. CONCLUSIONS The spread of the COVID-19 in China in its early phase was attributed primarily to population movement from Hubei, and effective governmental health emergency measures and adequate medical resources played important roles in subsequent control of epidemic and improved prognosis of affected individuals.### Competing Interest StatementThe authors have declared no competing interest.### Funding StatementThe study was partially supported by the Zhejiang University Special Scientific Research Fund for COVID-19 Prevention and Control### Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo external datasets or supplementary material

著录项

  • 作者单位

    Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;Nuffield Department of Population Health, University of Oxford;Second Affiliated Hospital of Zhejiang University School of Medicine;Hangzhou Mitigenomics Technology Inc.;Second Affiliated Hospital of Zhejiang University School of Medicine;Second Affiliated Hospital of Zhejiang University School of Medicine;;

  • 年度 2020
  • 总页数 24
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 医药、卫生;

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号